Mathematical Modelling and Optimization of Medication Regimens for Combination Immunotherapy of Breast Cancer
Bulletin of Mathematical Biology · 2025
DOI: 10.1007/s11538-025-01459-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of Mathematical Biology, 2025. Verfasst von Zixiao Xiong und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Mathematical Sciences, Harbin Engineering University, Harbin, 150001, Heilongjiang, China. Hauptthemen laut MEDLINE: Immunotherapy, Breast Neoplasms, Models, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Immunotherapy is an emerging and effective treatment for cancer. The mRNA-based cancer vaccines enhance the immune response to cancer cells by activating T cells. However, the cytotoxic T-lymphocyte antigen (CTLA-4) receptor signaling inhibits T-cell activation, thereby reducing the effectiveness of the mRNA-based vaccines. Fortunately, the anti-CTLA-4 monoclonal antibody therapy can block CTLA-4 signaling. Nevertheless, the use of anti-CTLA-4 antibodies is also accompanied by immunotoxic side effects. Therefore, an effective and safe medication regimen plays an essential role in the treatment of cancer. First, we develop a mathematical model to describe the interaction of mRNA-based cancer vaccines and anti-CTLA-4 antibodies under the tumor immune microenvironment. Secondly, by employing the method of Markov Chain Monte Carlo (MCMC), the model is parameterized using experimental data, and the simulations are in agreement with experimental results. Finally, the gradient descent method is designed to optimize the medication regimens to inhibit tumor growth and reduce the side effects. Additionally, we find that the anti-CTLA-4 antibody should be administered following vaccination, and the dose of the antibody should positively correlate with the dose of vaccine within a safe range. Our study provides a theoretical basis for the selection of treatment regimens for clinical trials from a mathematical perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Mathematical Sciences, Harbin Engineering University, Harbin, 150001, Heilongjiang, China.
- College of Mathematical Sciences, Harbin Engineering University, Harbin, 150001, Heilongjiang, China. lxue@hrbeu.edu.cn.
- School of Mathematical Sciences, Tiangong University, Tianjin, 300387, China. jzlei@tiangong.edu.cn.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Xiong, Z., Xia, Y., Xue, L., & Lei, J. (2025). Mathematical Modelling and Optimization of Medication Regimens for Combination Immunotherapy of Breast Cancer. Bulletin of Mathematical Biology. https://doi.org/10.1007/s11538-025-01459-5
Vancouver
Xiong Z, Xia Y, Xue L, Lei J. Mathematical Modelling and Optimization of Medication Regimens for Combination Immunotherapy of Breast Cancer. Bulletin of Mathematical Biology. 2025. doi:10.1007/s11538-025-01459-5
BibTeX
@article{Xiong2025,
author = {Xiong, Zixiao and Xia, Yunfei and Xue, Ling and Lei, Jinzhi},
title = {Mathematical Modelling and Optimization of Medication Regimens for Combination Immunotherapy of Breast Cancer},
journal = {Bulletin of Mathematical Biology},
year = {2025},
doi = {10.1007/s11538-025-01459-5}
}
EUVIMED